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Abstract Nuclear factor kappa B（NF-κB）is one of the best-characterized transcription factors playing
important roles in many cellular responses to a large variety of stimuli，including inflammatory cytokines, phorbol
esters, growth factors, and bacterial and viral products. The aim of this study is to demonstrate NF-κB expression in
the mouse cochlea and its enhancement in response to lipopolysaccharides（LPS）and kanamycin（KA）treatment.
Methods KA treatment consisted of subcutaneous KA injections at 700 mg/kg twice a day with an eight-hour
interval between the two injections for 3 or 7 days. For animals in the LPS treatment group, a single dose of 0.3 mg
LPS dissolved in 0.2 ml sterile saline were injected into both bullae through the tympanic membrane and kept there
for 3 hours. Animals in the control group received subcutaneous saline injection for 7 days. Following
immmunohistochemichal processing with rabbit polyclonal anti-NF-κB p65 antibodies, cryosections of the cochlea
were examined for expression of NF-κB p65 in various structures in the cochlea. Results NF-κB p65 expression,
identified by presence of brown reaction products characteristic of DAB immunohistochemistry, was visible in the
spiral ligament, spiral prominence, tectorial membrane（TM）, spiral ganglion and nerve fibers. Relatively weak
NF-κB p65 expression was also visualized in the organ of Corti. Within the organ of Corti, the inner hair cells（IHC）,
outer hair cells（OHC）, inner pillar cells（IP）, outer pillar cells（OP）, Deiter’s cells（DC）, and Böettcher’s cells
exhibited stronger staining than the inner sulcus cells, Hensen’s cells（HC）and Claudius’cells. No NF-κB p65
expression was seen in the nucleus of the IHC and OHC. NF-κB p65 expression was increased in animals exposed to
LPS or KA, demonstrating significant differences in the staining between control animals and LPS/KA-treated
animals. NF-κB p65 expression was not significantly different between LPS treated and KA treated animals or
between 3 and 7 days in KA-treated animals. Conclusion LPS and KA exposure increases expression of NF-κB
p65 in the mouse cochlea.
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Introductions
NF-κB is one of the most important transcription
factor playing a pivotal role in many cellular responses
to a wide variety of signals, including inflammatory
cytokines, phorbol esters, growth factors, bacterial and
viral products, oxidative stress, hypoxia/reoxygenation,
UV light and radio irradiation. NF-κB is present in the
cytoplasm of the majority of cell types. It serves as a
critical regulator of the inducible expression of genes
involved in processes of immunity and inflammation,
cell adhesion, as well as in cell growth and death［1］.
NF-κB was first described as a protein that bounds
specificically to a DNA sequence （5
’-GGGACTTTCC-3） in the intronic enhancer of the
immunoglobulin k light chain gene ［2］. NF-κB is a
member of the larger NF-κB/Rel family of
transcriptional factors, which includes p50（NF-κB 1）,
p52 （NF-κB2）, p65 （Rel A）, RelB, and C-Rel.
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NF-κB/Rel proteins exist as homo- or heterodimers and
are sequestered in an inactive form through
non-covalent interaction with an inhibitory protein
referred to as IκB. To date, some members of the IκB
family have been identified, all of them（IκB-a, IκB-b,
IκB-y, IκB-e, Bcl-3, p100, and p105） containing
multiple copies of a 30-33 amino acid sequence called
ankyrin repeats. The specific interaction between
ankyrin repeats and the Rel-homology domain of
NF-κB/Rel proteins prevents the nuclear translocation
of the NF-κB/IκB complex ［3, 4］. When cells are
appropriately stimulated with NF-κB inducers, the IκB
kinase （IKK） complex is activated, IκB is
phosphorylated at positions Ser32 and Ser36
（phosphorylations of other serines as well as tyrosines
and threonines have been also reported, but their
precise role is unclear at the moment）, and then
ubiquitinated on Lys22. These events trigger the rapid
degradation of IκB by the 26s protease, thereby
releasing active NF-κB. Finally, the released NF-κB
dimer translocates into the nucleus, where it binds DNA
and induces transcription of specific target genes.
The current study is aimed at demonstrating the
location of the NF-κB p65 proteins in the mouse
cochlea and studying the effects by KA and LPS
treatment on their expression.
Materials and methods
Experimental animals
Twenty four mice（20~25g）, purchased from Harlan
Sprague Dawley, Inc.（Indianapolis, IN）, were randomly
divided into four groups: a KA 3 day treatment group, a
KA 7 day treatment group, a LPS treatment group and a
control group. There were 6 animals in each group. The
animals had free access to water and a regular mouse
diet（Purina 5025, St. Louis, MO）, and were allowed 1
week of adaptation. Animal care was under the
supervision by the University of Michigan’s Unit for
Laboratory Animal Medicine（ULAM）. The Committee
on Use and Care of Animals approved all test protocols.
Drug administration
KA sulfate was purchased from USBTM Corporation
（Cleveland, OH）, and LPS from Sigma Chemical Co.
（St. Louis, MO）. KA was dissolved in saline at a concen⁃
tration of 44.7 mg/ml and was subcutaneously injected
at 700 mg/kg twice a day with an eight hours interval be⁃
tween the two injections. KA was administrated for 3 or
7 days before harvesting the temporal bone for the two
groups of animals receiving KA treatment, respectively.
For animals in the LPS treatment group, a single dose of
0.3 mg LPS dissolved in 0.2 ml sterile saline was inject⁃
ed into both bullae through the tympanic membrane and
kept ther for 3 hours. Animals in the control group re⁃
ceived subcutaneous saline injections for 7 days.
Tissue preparation
Animals were sacrificed via neck dislocation and the
bullae rapidly opened. Stapes were removed. The round
window membrane and cochlear tips were perforated
with a fine needle. The cochlea was gently perfused with
4% paraformaldehyde fixative in 10 mM PBS（pH 7.4）.
Temporal bones were immersed in the fixative for
overnight and rinsed in 10 mM PBS twice. Cochleae
were decalcified in 8% EDTA solution at 4℃ for a total
of 1.5 days, followed by rinsing in PBS. The cochleae
were then washed for 30 minutes in 10% sucrose, 2:1
solution of 10:30% sucrose, 1:1 solution of 10:30 %
sucrose, 1:2 solution of 10:30 % sucrose at room
temperature with rotation, and maintained overnight at
4℃ in 30% sucrose. The cochleae were placed in the
cryomold under dissecting microscope and filled
halfway with OCT. Embedded in OCT and oriented by
aligning an imaginary plane through the modiolus
parallel with the bottom of the embedding mold, the
mold was immediately placed in the dry ice/ethanol
bath. Five-micron sections were cut using a Leica
Cryomicrotom 3000. Sections were mounted on
Fisherbrand superfrost plus slides and stored in the
refrigerator at 4℃.
Immunohistochemical Staining
Immunohistochemical procedures have been de⁃
scribed in detail in other studies［5, 6］. Sections were im⁃
mersed at room temperature first in 0.3% Triton X 100
for 10 minutes and then in 0.3% hydrogen peroxide for
30 minutes. Sections were then rinsed twice in 10 mM
PBS. This was followed by incubation with diluted nor⁃
mal blocking serum（Vector Elite ABC kit）for 30 min⁃
utes and with 1： 24000 rabbit polyclonial an⁃
ti-NFκB-p65（primary）antibodies（Santa Cruz Biotech⁃
nology）for 30 minutes at room temperature. Biotinylat⁃
ed secondary antibody solution and vectastain Elite
ABC reagent were applied for 30 minutes. The sections
were rinsed again with PBS and allowed to react in sub⁃
strate medium containing 3’3-diaminobenzidine（DAB;
sigma）and hydrogen peroxide for 3 minutes before ob⁃
servation under light microscope. Incubation with prima⁃
ry antibodies was omitted for control sections.
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Results
NF-κB P65 expression was identified by presence
of brown reaction products characteristic of DAB
immunohistochemistry. Expression was graded based
upon the density of the reaction products, from light
brown（+）, to moderate brown（++）and to dark brown
（ +++）, with darker staining representing stronger
expression. Lack of reaction product staining was
graded with“-”, as seen in control sections that were
not exposed to the primary antibodies（see Table 1）.
Expression of NF-κB P65 in the cochlea in control
animals
In control animals, NF-κB p65 expression was
represented mainly by light brown(+ ) staining. The
staining was seen in the organ of Corti, spiral limbus,
tectorial membrane （TM）, spiral ligament, spiral
prominence, spiral ganglion and nerve fibers in all turns
throughout the cochlea. Of these structures, staining in
the organ of Corti was relatively weak compared to
others. Within the organ of Corti, NF-κB p65
expression was observed in the plasma of OHC and
IHC, HC, IP and OP, DC and TM, but not in the
nucleus, with relatively weak staining in inner sulcus
cells, Hensen’s cells and Claudius’cells. There was no
NF-κB p65 expression in the basilar membrane
（Figure.1） or the stria vascularis of normal group
（Figure 2）. In the spiral ganglion, expression of NF-κB
Tissues and cells
IHC plasm (nucleus）
OHC plasm (nucleus）
Inner pillar plasm(nucleus）
Outer pillar plasm(nucleus）
Deiter cell plasm(nucleus）
Hensen cell plasm(nucleus）
Boettcher cell plasm(nucleus）
Inner suclus plasm(nucleus）
Claudius cell plasm (nucleus)
Tectoral membrane
Stria vascularis
Spiral ligament
Spiral prominence
spiral ganglion plasm (nucleus）
Fiber of spiral nerve
Basal membrane
Control
+(-)
+(-)
+(-)
+(-)
+(-)
+(-)
+(-)
+(-)
+(-)
++
-
+
+
+(-)
+
-
LPS
++(-)
++(-)
++(-)
++(-)
++(-)
++(-)
++(-)
++(-)
++(-)
++
++
++
++
++(+)
++
-
KA 3 day treatment
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
++
+
+++
+++
+++(++)
++
-
KA 7 day treatment
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
+++(+)
++
+
+++
+++
+++(++)
++
-
Table 1. Strength of NF-κB p65 expression in various structures in the mouse cochlea
Note: NF-κB P65 expression was identified by presence of brown reaction products characteristic of DAB immunohistochemistry.
Expression was graded based upon the density of the reaction products, + presents light brown, ++ is moderate brown and +++ is
dark brown with darker staining representing stronger expression. Lack of reaction product staining was expressed with“-”
Figure1. Positive expression of NF-κB p65(+) is present
in the plasma of the OHC and IHC, HC, OP and IP, D and
TM in this cochlea from a control animal. There is no
NF-κB p65 activity of in the nucleus in the OHC, IHC,
HC, OP, IP, D and the basilar membrane（B）.（X400）
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p65 was present in the plasma, nucleus and nerve fibers
（Figure.3）.
NF- κB P65 expression in LPS treated animals
Increased expression of NF-κB p65 was seen in
the plasma of OHC and IHC, HC, IP and OP, DC and
TM with darker staining, compared to control animals.
Again, there was no NF-κB p65 expression in the
nucleus of these cells or in the basilar membrane
（Figure.4）. Increased levels of NF-κB p65 expression
was also seen in the spiral prominence（Figure.5）, and
in the plasma, nucleus and nerve fibers of the spiral
ganglion（Figure.6）. Low level NF-κB p65 expression
was present in the spiral ligament in this group of
animals.
NF-κB p65 expression in KA treated animals
In the two groups of animals treated with KA,
expression of NF-κB P65 in the plasma of OHC and
IHC, HC, OP and IP, DC and TM in KA treated animals
appeared to be further increased, compared to both
control and LPS treated animals. The nucleus of these
cells, however, again showed no NF-κB p65 expression.
Also, there was no staining in the basilar membrane
（Figure.7）. The stria vascularis showed light staining as
in LPS treated animals. Much increased NF-κB p65
expression was also observed in the spiral ligament,
Figure 2. The stria
vascularis in a control
animal shows negative
staining（-）for NF-κB
p65（☆）, as compared
to the positive NF-κB
p65 activity in the
spiral ligament（★）and
spiral prominence（➡）.
（× 300）.
Figure3. Positive
NF-κB p6 expres⁃
sion in the plasma,
nucleus（➡） and
nerve fiber（ ）of
the spiral ganglion
from a control ani⁃
mal.（× 350）
Figure 4. Increased
NF-κB p65 expression
（++） in the plasma of
OHC and IHC, OP and
IP, D and TM in the
cochlea from an LPS
treated animal. Note
there is no expression of
NF-κB p65 in the
nucleus in the OHC,
IHC, HC, OP, IP, D and
the basilar membrane
（B）.（× 400）
Figure 5. light NF-κB
p65 staining in the stria
vascularis（☆） in a
LPS treated animal.
Stronger NF-κB p65
expression can be seen
in the spiral ligament
（★）and spiral promi⁃
nence（➡）（× 300）
Figure 6. NF-κB p65
expression（++）in the
plasma, nucleus（➡）
and nerve fiber（ ）of
the spiral ganglion in
an LPS treated animal.
（× 350）
Figure 7. Strong NF-κB
p65 expression (+++ ) in
the plasma of OHC and
IHC, HC, OP and IP, D
and TM in the cochlea
from a KA treated ani⁃
mal. No NF-κB p65 ex⁃
pression in the nucleus
in the OHC, IHC, HC,
OP, IP, D and the basilar
membrane（B）（× 450）
Figure 8. Light
NF-κB p65 staining in
the stria vascularis
（☆） in a KA treated
animal. Stronger
NF-κB p65 expression
can be seen in the spi⁃
ral ligament（★） and
spiral prominence（➡）
（× 300）.
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spiral prominence（Figure.8）, and in the plasma,
nucleus and nerve fiber of the spiral ganglion
（Figure.9）, compared to the control and LPS treated
animals.
The differences between control and LPS/
KA-treated animals concerning NF-κB p65 expression
were statistically significant. There was no statistically
significant difference in NF-κB p65 expression between
3 and 7 days of KA treatment.
Discussion
NF-κB is a member of the Rel family of
transcriptional activator proteins and has a diverse
variety of actions in the central nervous system. NF-κB
has been found to regulate many genes that have
important functions in conditions such as inflammation
and immunity ［1］. All members of the Rel family of
transcription factors share sequence homology. The
subunits can dimerize to be homodimers or heterodimers
although NF-κB exists predominantly as a heterodimer
of p50 and p65. There are three forms of NF-κB present
in neurons in vivo, namely, constitutive NF-κB activity
in the nucleus, free inhibitory protein IкB, and inactive
NF-κB in the cytoplasm and synapse closely bound to
the inhibitory protein IкB, which keeps it inactive.
Several extracellular stimuli, including cytokines,
viruses, bacterial LPS, NO, and oxidative stress, can
cause the phosphorylation and consequent
ubiquitination of the IκB protein, resulting in the
translocation of active NF-κB from the cytoplasm to the
nucleus. Activated NF-κB binds DNA in the nucleus
and hence regulates gene expression. Several genes
have NF-κB binding sites, including enzymes（such as
the inducible nitric oxide synthase [iNOS] and
cyclooxygenase isoform 2）, neuropeptides （such as
dynorphin and proenkephaloin）, and adhesion molecules
（such as cell adhesion molecule-1 and intercellular
adhesion moleculaw-1）.
The current study demonstrated positive expression
of NF-κB p65 in a variety of structures in the normal
cochlea, including many types of cells in the organ of
Corti, the spiral limbus, TM, spiral ligament, spiral
ganglion and nerve fibers. This indicates the existence
of NF-κB in these cells and tissues, likely the inhibitory
IκB with an inactive form. Our study showed no NF-κB
p65 expressions in the nucleus of cells in the organ of
Corti, nor in the basal membrane and stria vascularis.
Positive NF-κB p65 expression was also present in the
plasma and nucleus of the spiral ganglion. Baldwin
reported that NF-κB usually exists in an inactive form,
（i.e., p50 and p65 dimer combined with the inhibitory
IκB） in the resting condition［7］. It is not clear if the
NF-κB p65 expression in the spiral ganglion nucleus
observed in this study represents active NF-κB p65
activity.
NF-κB p65 expression in the above mentioned
structures appeared to have been enhanced following
exposure to LPS, suggesting activation of NF-κB p65 by
LPS stimulation, which induces transduction of NF-κB
from the plasma to the nucleus. Inside the nucleus,
NF-κB will be activated through combining with DNA
and regulate gene expression. The increased NF-κB
p65 expression in the cochlea in response to middle ear
exposure to LPS indicates an inflammatory reaction in
the cochlea induced by presence of stimulating factors
in the middle ear.
Jiang et al reported progressive destruction of hair
cells by kanamycin, with largely preserved auditory
function and structures after 7 days of treatment, which
allowed investigation of early events in drug-induced
cell death. NF-B expression increased at 3 hr, 3 days,
and 7 days following kanamycin treatment, with no
labling in nuclei of outer hair cells. Concomitant
injections of antioxidants, 2,3-dihydroxybenzoic acid or
salicylate（which prevents cell death induced by
kanamycin）, promoted translocation of NF-B into the
nuclei of outer hair cells［8］. Our results seem to agree
with those in Jiang’s study. Significantly increased
NF-κB p65 expression was seen in animals receiving
systemic KA, suggesting its strong effects on NF-κB
p65 in the cochlea. Masatsugu also showed in an
immunohistochemical study that there was nuclear
translocation of both p65 and p50 in the lateral wall
after noise exposure. There seems to be a close
association between p65 and p50. Expression of
inducible nitric oxide synthase was also enhanced by
noise exposure. Their results suggest that NF-κB may
Figure 9. NF-κB
p65 expression in
the plasma, nucleus
（➡）and nerve fi⁃
ber（ ）of the spi⁃
ral ganglion in a
KA treated animal.
（× 350）
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have a detrimental role in the response to acoustic
overstimulation in the cochlea of mice ［9］. As an
antibiotic, KA does not induce inflammation in the
cochlea. We speculate that the strong NF-κB p65
expression seen in this study may represent an immune
response in the cochlea as part of the body’s response to
KA exposure. This immune response may also cause
damage in various structures in the cochlea. Whether
KA can cause cochlear damage by directly activating
NF-κB p65 needs to be further studied. An increased
understanding of this issue will likely provide new
knowledge in KA ototoxicity and hopefully lead to
improved prevention and treatment.
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